Genmab Reports Phase 2 Colorectal Cancer Response Rates of 75% and 67%

Updated data for petosemtamab plus chemotherapy showed ORR of 75% in first-line and 67% in second-line metastatic colorectal cancer; ORR was 81% in first-line left-sided tumors. Median follow-up was 5.9 and 7.1 months, respectively, and most previously unconfirmed responses were confirmed.